Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruochan, Pei, Siya, Chen, Yayu, Tan, Linxia, Xue, Ying, Liu, Shao, Huang, Yan, Fan, Xuegong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295557/
https://www.ncbi.nlm.nih.gov/pubmed/34307428
http://dx.doi.org/10.3389/fmed.2021.701061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295557/
https://www.ncbi.nlm.nih.gov/pubmed/34307428
http://dx.doi.org/10.3389/fmed.2021.701061

Ejemplares similares